Levetiracetam Tablet, For Suspension
NDC Package 66993-101-60
Package Information
Levetiracetam tablets is levetiracetam is used to treat seizures (epilepsy). This formulation utilizes a tablet, for suspension delivery system. Marketed by Prasco Laboratories, this product is identified by NDC 66993-101 and is authorized under FDA application NDA207958.
Identification & Billing
- RxCUI: 1736045 - levETIRAcetam 250 MG Tablet for Oral Suspension
- RxCUI: 1736045 - levetiracetam 250 MG Tablet for Oral Suspension
- RxCUI: 1736048 - levETIRAcetam 500 MG Tablet for Oral Suspension
- RxCUI: 1736048 - levetiracetam 500 MG Tablet for Oral Suspension
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 66993 - Prasco Laboratories
- 66993-101 - Levetiracetam
- 66993-101-60 - 60 BLISTER PACK in 1 CARTON / 1 TABLET, FOR SUSPENSION in 1 BLISTER PACK (66993-101-51)
- 66993-101 - Levetiracetam
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 66993-101-60 identifies a specific commercial package of 60 blister pack in 1 carton / 1 tablet, for suspension in 1 blister pack (66993-101-51) of Levetiracetam, a human prescription drug labeled by Prasco Laboratories. This product is billed for "EA" each discreet unit and contains an estimated amount of 60 billable units per package. This tablet, for suspension is formulated for oral use and contains levetiracetam as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Prasco Laboratories on January 20, 2025. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
Levetiracetam is used to treat seizures (epilepsy). It belongs to a class of drugs known as anticonvulsants. Levetiracetam may decrease the number of seizures you have.
How is this Prasco Laboratories product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 66993010160. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 60 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.